Lorient Capital, a private equity firm specializing in healthcare, has closed its third fund—Lorient Healthcare Fund III—at $500 million in commitments, surpassing its original $350 million target. The fund closed on June 30 and was significantly oversubscribed.
Focused on founder-led companies in the healthcare middle market, Lorient brings deep sector knowledge, operational expertise, and a systematic approach to scaling businesses with strong missions. The firm has a proven history of driving improvements in patient care, workforce efficiency, and healthcare access throughout the United States.
“This fund is a major milestone in our mission to back companies that aim to improve the healthcare system while delivering sustainable value,” said David Berman and Jordan Broome, Co-Managing Partners at Lorient. “We appreciate the trust from our longstanding partners and welcome the support of new investors who believe in the dual promise of strong returns and meaningful impact.”
Lorient primarily targets control positions in healthcare services, providers, and technology-enabled businesses. Its strategy focuses on sectors undergoing transformation—such as consumer-driven care, behavioral health, post-acute services, provider enablement, and tech-enabled models—where Lorient’s operational structure can be a growth catalyst.
The firm’s portfolio companies work to enhance care quality, extend services to rural and underserved communities, address staffing shortages, and integrate services for vulnerable populations. Quality of care is one of Lorient’s five operational pillars and is monitored closely in collaboration with clinical experts using its proprietary tools.
Since its founding, Lorient has made 20 platform investments and executed over 75 add-on acquisitions. The firm’s nine successful exits demonstrate its ability to grow and scale healthcare businesses effectively.
Central to Lorient’s model is Morpheus, its proprietary tech platform that synthesizes financial, operational, and clinical data into real-time insights. More than a reporting tool, Morpheus integrates into portfolio companies’ operations to help benchmark performance, close operational gaps, and guide strategy.
“Morpheus is our growth engine,” said Broome. “It empowers our portfolio companies with actionable data and capabilities to expand efficiently and improve patient outcomes.”
With Fund III, Lorient plans to continue its partnership with strong healthcare management teams to scale businesses that align operational discipline with clinical quality. The successful fundraise further strengthens Lorient’s role as a strategic partner to healthcare entrepreneurs and investors, positioning the firm for continued success in its hands-on, operations-first approach to value creation.
Source: Lorient Capital
